ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 159 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2020. The put-call ratio across all filers is 1.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $22,243 | -77.1% | 13,989 | -10.2% | 0.00% | – |
| Q4 2022 | $97,082 | +10.3% | 15,583 | +20.4% | 0.00% | – |
| Q3 2022 | $88,000 | +15.8% | 12,940 | +7.9% | 0.00% | – |
| Q2 2022 | $76,000 | -6.2% | 11,992 | -30.8% | 0.00% | – |
| Q1 2022 | $81,000 | +62.0% | 17,332 | +73.1% | 0.00% | – |
| Q4 2021 | $50,000 | -80.1% | 10,015 | -15.7% | 0.00% | -100.0% |
| Q2 2021 | $251,000 | -16.9% | 11,875 | +10.1% | 0.00% | 0.0% |
| Q1 2021 | $302,000 | +15.7% | 10,783 | +7.5% | 0.00% | 0.0% |
| Q4 2020 | $261,000 | -8.4% | 10,035 | +31.1% | 0.00% | 0.0% |
| Q3 2020 | $285,000 | -30.0% | 7,655 | -3.5% | 0.00% | -50.0% |
| Q2 2020 | $407,000 | -26.9% | 7,932 | -15.1% | 0.00% | -33.3% |
| Q4 2019 | $557,000 | +48.9% | 9,341 | -8.4% | 0.00% | +50.0% |
| Q3 2019 | $374,000 | -21.8% | 10,194 | -0.8% | 0.00% | -33.3% |
| Q2 2019 | $478,000 | +2.6% | 10,279 | -11.4% | 0.00% | 0.0% |
| Q1 2019 | $466,000 | -11.9% | 11,600 | +0.9% | 0.00% | -25.0% |
| Q4 2018 | $529,000 | -13.1% | 11,498 | -16.3% | 0.00% | 0.0% |
| Q3 2018 | $609,000 | +8.9% | 13,730 | -3.8% | 0.00% | 0.0% |
| Q2 2018 | $559,000 | -46.6% | 14,271 | -1.3% | 0.00% | -42.9% |
| Q1 2018 | $1,046,000 | -4.5% | 14,463 | -13.0% | 0.01% | -12.5% |
| Q4 2017 | $1,095,000 | +39.7% | 16,631 | +6.3% | 0.01% | +14.3% |
| Q3 2017 | $784,000 | +31.1% | 15,640 | +21.1% | 0.01% | +16.7% |
| Q2 2017 | $598,000 | +23.8% | 12,912 | -5.7% | 0.01% | +20.0% |
| Q1 2017 | $483,000 | +124.7% | 13,686 | -20.4% | 0.01% | +150.0% |
| Q4 2016 | $215,000 | -0.9% | 17,198 | +10.0% | 0.00% | -33.3% |
| Q3 2016 | $217,000 | +18.6% | 15,634 | -15.6% | 0.00% | +50.0% |
| Q2 2016 | $183,000 | -40.8% | 18,533 | +1.3% | 0.00% | -50.0% |
| Q1 2016 | $309,000 | -30.7% | 18,295 | -8.6% | 0.00% | -20.0% |
| Q4 2015 | $446,000 | +85.8% | 20,020 | +104.3% | 0.01% | +66.7% |
| Q3 2014 | $240,000 | +30.4% | 9,800 | -15.6% | 0.00% | +50.0% |
| Q2 2014 | $184,000 | -25.8% | 11,611 | -29.1% | 0.00% | -33.3% |
| Q1 2014 | $248,000 | – | 16,385 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $69,675,000 | 19.39% |
| Endurant Capital Management LP | 207,293 | $5,390,000 | 1.94% |
| Bellevue Group AG | 5,138,451 | $133,599,000 | 1.53% |
| Rhenman & Partners Asset Management AB | 592,225 | $15,398,000 | 1.26% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,562,869 | $40,635,000 | 0.93% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 31,434 | $817,000 | 0.62% |
| WASATCH ADVISORS LP | 3,998,010 | $103,949,000 | 0.51% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,201,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $13,000,000 | 0.42% |
| DCF Advisers, LLC | 38,500 | $1,001,000 | 0.41% |